Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Cancer Treatment and Research|October 9, 2021
Acute Promyelocytic Leukemia: Update on Risk Stratification and Treatment PracticesAmandeep Salhotra, Matthew Mei
Hematology/Oncology Clinics of North America|January 3, 2026
Selection of a Salvage Regimen for Relapsed or Refractory Classic Hodgkin Lymphoma in the Era of Novel TherapiesAnnie Xiao, Matthew Mei
Clinical Lymphoma, Myeloma & Leukemia|December 14, 2017
How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCTMatthew Mei, Robert Chen
Journal of the National Comprehensive Cancer Network : JNCCN|August 8, 2014
The role of transplant in multiple myelomaMatthew Mei, George Somlo
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 22, 2013
Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotinMatthew Mei, Sandra Thomas, Robert Chen
Current Hematologic Malignancy Reports|January 7, 2021
Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?Tamer Othman, Alex Herrera, Matthew Mei
Cancer Treatment and Research|October 9, 2021
Current and Emerging Therapies for Acute Myeloid LeukemiaBrian Ball, Matthew Mei, Salman Otoukesh, et al.
Neurochemical Research|September 28, 2005
P38 activation mediates amyloid-beta cytotoxicityXiongwei Zhu, Matthew Mei, Hyoung-Gon Lee, et al.
Pageof 8